Swiss National Bank’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-96,174
| Closed | -$3.31M | – | 2546 |
|
|
2020
Q3 | $3.31M | Buy |
96,174
+3,400
| +4% | +$72.4K | ﹤0.01% | 1435 |
|
|
2020
Q2 | $1.55M | Buy |
92,774
+19,100
| +26% | +$324K | ﹤0.01% | 1852 |
|
|
2020
Q1 | $1.06M | Buy |
73,674
+1,800
| +3% | +$46K | ﹤0.01% | 1800 |
|
|
2019
Q4 | $2.41M | Buy |
71,874
+2,400
| +3% | +$67.1K | ﹤0.01% | 1620 |
|
|
2019
Q3 | $1.46M | Hold |
69,474
| – | – | ﹤0.01% | 1846 |
|
|
2019
Q2 | $1.45M | Sell |
69,474
-3,900
| -5% | -$80.3K | ﹤0.01% | 1901 |
|
|
2019
Q1 | $1.64M | Buy |
73,374
+6,200
| +9% | +$146K | ﹤0.01% | 1790 |
|
|
2018
Q4 | $1.61M | Buy |
67,174
+2,700
| +4% | +$69.9K | ﹤0.01% | 1707 |
|
|
2018
Q3 | $1.76M | Hold |
64,474
| – | – | ﹤0.01% | 1799 |
|
|
2018
Q2 | $1.73M | Hold |
64,474
| – | – | ﹤0.01% | 1791 |
|
|
2018
Q1 | $2.05M | Buy |
64,474
+23,900
| +59% | +$841K | ﹤0.01% | 1621 |
|
|
2017
Q4 | $1.53M | Buy |
40,574
+3,600
| +10% | +$116K | ﹤0.01% | 1807 |
|
|
2017
Q3 | $917K | Hold |
36,974
| – | – | ﹤0.01% | 2109 |
|
|
2017
Q2 | $760K | Hold |
36,974
| – | – | ﹤0.01% | 2216 |
|
|
2017
Q1 | $803K | Buy |
36,974
+5,500
| +17% | +$113K | ﹤0.01% | 2157 |
|
|
2016
Q4 | $644K | Hold |
31,474
| – | – | ﹤0.01% | 2281 |
|
|
2016
Q3 | $472K | Hold |
31,474
| – | – | ﹤0.01% | 2374 |
|
|
2016
Q2 | $341K | Buy |
31,474
+9,200
| +41% | +$125K | ﹤0.01% | 2493 |
|
|
2016
Q1 | $292K | Buy |
22,274
+8,974
| +67% | +$140K | ﹤0.01% | 2499 |
|
|
2015
Q4 | $245K | Buy |
+13,300
| New | +$246K | ﹤0.01% | 2542 |
|
Swiss National Bank's AIMT Position: Q4 2020 in Review
Swiss National Bank sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 96,174 shares — an estimated $3.31M sold.
Swiss National Bank first reported a position in AIMT in Q4 2015 and held it in 20 quarters. The position peaked at $3.31M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Swiss National Bank reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Swiss National Bank sold 96,174 Aimmune Therapeutics shares in Q4 2020, an estimated $3.31M.
- Swiss National Bank first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 20 quarters.
- Swiss National Bank's Aimmune Therapeutics position peaked at $3.31M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Swiss National Bank's 13F filing for Q4 2020, filed 5 Feb 2021.